POS1245 MORTALITY OF COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: COMPARISON TO THE GENERAL POPULATION IN MÉXICO

• Published in: Annals of the rheumatic diseases Vol. 80; no. Suppl 1; pp. 905 - 906
• Main Authors: Martínez-Martínez, M. U., Irazoque-Palazuelos, F., Rodriguez-Reyne, T. S., Zamora, E., Castillo Ortiz, A., Zazueta, B. E., Duran Barragan, S., Rull-Gabayet, M., Moctezuma-Ríos, J. F., Jimenez Jimenez, X., Martin-Nares, E., Cervantes-Rosete, D., Vega-Morales, D., Xibille Friedmann, D. X., Barragán-Garfías, A., Alvarez Hernandez, E., Vázquez-Del Mercado Espinosa, M., Pacheco Tena, C. F., Alpizar-Rodriguez, D.
• Format: Journal Article
• Language: English
• Published: 01.06.2021
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2021-eular.3447

Background: COVID-19 outcomes in Mexican patients with rheumatic diseases (RDs) in comparison to general population patients are unknown. Objectives: To compare mortality and hospitalization of COVID-19 patients with RDs and those without. Methods: We included for this study all the Mexican patients with RDs and COVID-19 registered from April 17 th to October 30 th , 2020 in the COVID-19 Global Rheumatology Alliance registry. We compare clinical and demographic characteristics of patients with RDs and COVID-19 to patients with COVID-19 that were selected randomly from the Mexican Epidemiology database (1:3). A logistic regression analysis was performed to adjust for confusion variables. Results: We included 322 patients with COVID-19 and RDs and 969 controls without RDs. Table 1 shows the demographic characteristics and comorbidities of both groups. Bivariate analysis showed that patients with RDs had higher mortality, were older, and were more frequently hospitalized. Comorbidities, such as diabetes, hypertension, cardiovascular and renal diseases were also more frequent in patients with RDs. In the multivariate analysis, having a RD was no longer associated with mortality (Figure 1). Figure 1. Multivariate analysis of mortality Conclusion: Patients with RDs had higher comorbidities, hospitalizations, and mortality than the general population in the bivariate analysis. However, adjusted multivariate analysis showed that the odds for mortality were not increased because of having a RD. These findings suggest that the increased mortality of Mexican patients with RDs may be explained by the higher frequency of comorbidities in this population. Table 1. Comparison of patients with COVID-19 with and without RDs COVID-19 patients without RDs COVID-19 patients with RDs p-value N 969 323 Age (mean (SD)) 42.6 (17.4) 51.2 (13.9) <0.001 Sex = Male (%) 455 (47.0) 55 (17.0) <0.001 Deceased = Yes (%) 55 (5.7) 43 (13.3) <0.001 Hospitalization = Hospitalized (%) 164 (16.9) 152 (47.1) <0.001 Intubation = Yes (%) 27 (2.8) 32 (11.8) <0.001 COPD_Asthma = Yes (%) 37 (3.8) 15 (4.6) 0.522 Diabetes = Yes (%) 114 (11.8) 49 (15.2) 0.116 Obesity = Yes (%) 128 (13.3) 21 (6.5) 0.001 Hypertension = Yes (%) 152 (15.8) 88 (27.2) <0.001 Cardiovascular disease = Yes (%) 19 (2.0) 14 (4.3) 0.02 CRF = Yes (%) 22 (2.3) 17 (5.3) 0.007 Pregnancy = Yes (%) 5 (0.5) 2 (0.6) 0.827 Smoker = Yes (%) 86 (8.9) 10 (3.1) 0.001 Abbreviations: RDs, rheumatic diseases; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure. Disclosure of Interests: None declared